There hasn’t been any research that looks at the connections between bone marrow adiposity (BMA), bone histomorphometry (BH), and glycemic control in premenopausal women with type 2 diabetes (T2DM). Researchers wanted to see how glycemic management affected BMA, how BH parameters correlated with BMA, and how BMA correlated with the use of hypoglycemic medications and bone mineral density (BMD). This was cross-sectional research that looked at 26 premenopausal women with T2DM who were split into two groups: those with HbA1c less than 7% and those with HbA1c greater than 7%. BMA parameters and the number of peri-trabecular adipocytes split by bone surface were assessed. The static and dynamic characteristics of the BH, as well as serum insulin-like growth factor-1, were examined. The GC and PC groups’ BMA results were compared. Correlations were calculated. In PC, Ad.N, Ad.Pm, and Ad.Ar were all higher. HbA1c is positively associated with Ad.N/BS, while Ad.N/BS is negatively connected with O.Th and OS/BS. Except for Ad.N/BS, there were positive and negative associations between insulin and metformin usage and all adipocyte markers. The BMA was adversely associated with structural characteristics. BMD of the femoral neck and whole femur were shown to be inversely linked to Ad.V/Ma.V.

Poor glycemic management is linked to BMA hyperplasia and hypertrophy, as well as decreased BV/TV. Ad.N/BS, a novel BMA measure, is positively associated with HbA1c and adversely related to O.Th. The use of insulin appears to increase the growth of BMA, whereas metformin appears to have the reverse effect. These data imply that a rise in BMA may have a role in T2DM bone disease; however, effective glycemic management may help avoid it.